RXRX
Recursion Pharmaceuticals Inc
3.70$
-8.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +3.6% | -14.7% | +39.1% | -6.4% | +99.4% | -9.9% | -0.2% | +7.5% | +5.3% | -9.1% | -9.5% | |
| – | +6.7% | -21.6% | +52.0% | -9.2% | +50.6% | -18.2% | +0.5% | +21.6% | +13.8% | -12.7% | -15.0% | |
| – | +1.1% | -23.5% | +58.4% | -9.8% | +39.0% | -15.8% | +5.5% | +24.9% | +12.6% | -11.9% | -16.6% | |
| – | +1.1% | -23.5% | +58.4% | -9.8% | +39.0% | -15.8% | +5.5% | +24.9% | +12.6% | -11.9% | -16.6% | |
| – | -2.2% | -16.0% | -2.8% | -10.7% | +2,080.3% | -6.2% | -53.2% | +1.4% | +12.5% | -44.9% | +5.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.3% | +0.0% | +0.0% | +0.0% | +186.0% | +6.2% | +3.9% | -1.4% | +0.1% | -1.2% | +0.1% | |
| – | -7.6% | -9.2% | +15.5% | -10.8% | +885.1% | 0.0% | +1.6% | -5.6% | -3.9% | -5.1% | -3.8% | |
| – | -1.3% | -17.6% | +22.2% | +5.5% | +104.9% | -10.3% | +3.2% | -8.0% | -2.6% | -8.3% | -5.4% | |
| – | -1.0% | -20.7% | +16.5% | +26.5% | +72.2% | -24.3% | +15.5% | -5.4% | -4.8% | -12.2% | -7.6% | |
| – | +1.8% | -0.6% | +173.3% | -1.6% | +35.1% | -8.0% | +0.2% | -0.2% | +6.4% | +2.7% | +1.5% | |
| – | -7.3% | +29.4% | -26.5% | -39.9% | +856.3% | +16.1% | -23.0% | -27.9% | +30.0% | +12.3% | -37.7% | |
| – | -2.2% | -2.7% | +2,040.1% | -10.5% | -7.3% | -13.5% | -13.7% | -16.2% | -19.6% | -24.9% | -33.8% | |
| – | +5.8% | -13.4% | +45.7% | -10.2% | +97.3% | -9.7% | -1.6% | +13.9% | +8.0% | -9.4% | -10.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +8.8% | +1.2% | +2.6% | +16.7% | +18.9% | +19.9% | +3.6% | +7.1% | +17.8% | +0.5% | +0.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.